Total Payments
$368,665
2024 Payments
$93,521
Companies
37
Transactions
1,301
Medicare Patients
1,933
Medicare Billing
$261,223
Payment Breakdown by Category
Other$257,383 (69.8%)
Travel$38,988 (10.6%)
Consulting$25,510 (6.9%)
Research$25,000 (6.8%)
Food & Beverage$21,688 (5.9%)
Education$96.02 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $211,705 | 101 | 57.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $45,360 | 15 | 12.3% |
| Travel and Lodging | $38,988 | 102 | 10.6% |
| Consulting Fee | $25,510 | 7 | 6.9% |
| Unspecified | $25,000 | 1 | 6.8% |
| Food and Beverage | $21,688 | 1,065 | 5.9% |
| Entertainment | $317.50 | 8 | 0.1% |
| Education | $96.02 | 2 | 0.0% |
Payments by Type
General
$343,665
1,300 transactions
Research
$25,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $93,855 | 227 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $77,206 | 111 | $0 (2024) |
| CONMED Corporation | $36,541 | 12 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31,576 | 137 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $25,201 | 14 | $0 (2020) |
| Synergy Pharmaceuticals Inc | $25,093 | 60 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $24,961 | 22 | $0 (2024) |
| Allergan, Inc. | $22,374 | 192 | $0 (2020) |
| Gilead Sciences, Inc. | $17,593 | 134 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $5,920 | 38 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93,521 | 202 | Phathom Pharmaceuticals, Inc. ($77,206) |
| 2023 | $29,877 | 71 | ABBVIE INC. ($22,553) |
| 2022 | $34,521 | 124 | ABBVIE INC. ($22,674) |
| 2021 | $20,914 | 78 | AbbVie Inc. ($10,986) |
| 2020 | $12,765 | 79 | AbbVie Inc. ($9,064) |
| 2019 | $49,553 | 234 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($18,949) |
| 2018 | $46,293 | 247 | CONMED Corporation ($23,497) |
| 2017 | $81,222 | 266 | Cumberland Pharmaceuticals, Inc. ($25,087) |
All Payment Transactions
1,301 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: LIVER DISEASE | ||||||
| 12/23/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $7.92 | General |
| Category: LIVER DISEASE | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $81.76 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $0.98 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/03/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $10.32 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $4.71 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $2.14 | General |
| Category: LIVER DISEASE | ||||||
| 11/26/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $7.93 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug), Linzess | Food and Beverage | Cash or cash equivalent | $15.13 | General |
| Category: GI | ||||||
| 11/18/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: LIVER DISEASE | ||||||
| 11/14/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $299.59 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $142.60 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | Cash or cash equivalent | $22.55 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,973.00 | General |
| 11/06/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | In-kind items and services | $638.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Omeclamox Efficacy | Cumberland Pharmaceuticals, Inc. | $25,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 245 | 282 | $148,323 | $27,071 |
| 2022 | 14 | 635 | 764 | $384,400 | $78,991 |
| 2021 | 11 | 570 | 720 | $341,870 | $79,368 |
| 2020 | 7 | 483 | 703 | $291,750 | $75,792 |
Total Patients
1,933
Total Services
2,469
Medicare Billing
$261,223
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 56 | $22,596 | $6,038 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $22,032 | $5,060 | 23.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 68 | $13,922 | $4,601 | 33.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 31 | $17,143 | $4,597 | 26.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 34 | 34 | $41,990 | $3,607 | 8.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $25,690 | $2,448 | 9.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 33 | $4,950 | $721.24 | 14.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 132 | 228 | $34,200 | $16,621 | 48.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 73 | 73 | $102,200 | $9,832 | 9.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 86 | $15,050 | $9,377 | 62.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 71 | 76 | $95,000 | $8,463 | 8.9% |
| 93976 | Ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2022 | 39 | 39 | $19,500 | $5,372 | 27.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 66 | 66 | $10,000 | $5,205 | 52.1% |
| 46221 | Removal of external hemorrhoids by rubber banding | Office | 2022 | 12 | 19 | $7,600 | $5,125 | 67.4% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2022 | 39 | 39 | $11,700 | $3,996 | 34.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 16 | 16 | $25,600 | $3,133 | 12.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 20 | 21 | $27,300 | $2,680 | 9.8% |
| 46221 | Removal of external hemorrhoids by rubber banding | Facility | 2022 | 15 | 15 | $6,000 | $2,332 | 38.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 12 | $19,200 | $2,303 | 12.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $4,250 | $2,073 | 48.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 27 | 32 | $4,800 | $2,028 | 42.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 24 | 25 | $2,000 | $449.85 | 22.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 154 | 271 | $41,450 | $27,027 | 65.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 84 | 84 | $117,600 | $12,174 | 10.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 65 | 65 | $16,300 | $8,135 | 49.9% |
About Dr. Devjit Nayar, MD
Dr. Devjit Nayar, MD is a Gastroenterology healthcare provider based in Hoboken, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093787806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Devjit Nayar, MD has received a total of $368,665 in payments from pharmaceutical and medical device companies, with $93,521 received in 2024. These payments were reported across 1,301 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($211,705).
As a Medicare-enrolled provider, Nayar has provided services to 1,933 Medicare beneficiaries, totaling 2,469 services with total Medicare billing of $261,223. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Specialist, Gastroenterology
- Location Hoboken, NJ
- Active Since 02/06/2006
- Last Updated 01/12/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1093787806
Products in Payments
- VOQUEZNA (Drug) $77,206
- SKYRIZI (Biological) $33,889
- Omeclamox (Drug) $25,186
- Trulance (Drug) $25,093
- ZEPOSIA (Drug) $24,947
- SpaceBander Hemorrhoid Banding Device (Device) $23,291
- XIFAXAN (Drug) $22,777
- RINVOQ (Biological) $19,829
- LINZESS (Drug) $19,470
- HUMIRA (Biological) $18,673
- Vemlidy (Drug) $16,553
- Humira (Biological) $15,760
- TRULANCE (Drug) $10,673
- UCERIS (Drug) $3,621
- VIBERZI (Drug) $2,998
- Linzess (Drug) $521.05
- Alinia Tablets 500mg 30 count bottle (Drug) $423.43
- Amitiza (Drug) $333.35
- XELJANZ (Drug) $283.57
- ZENPEP (Drug) $255.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.